- |||||||||| TMV-018 / Merck (MSD), Max Planck Institute
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract (clinicaltrials.gov) - Nov 25, 2020
P1, N=0, Withdrawn,
N=15 --> 0 | Trial completion date: Dec 2023 --> Nov 2020 | Initiation date: Jun 2020 --> Nov 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Nov 2020
- |||||||||| TMV-018 / Merck (MSD), Max Planck Institute
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract (clinicaltrials.gov) - Jun 5, 2020
P1, N=15, Not yet recruiting,
N=15 --> 0 | Trial completion date: Dec 2023 --> Nov 2020 | Initiation date: Jun 2020 --> Nov 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Nov 2020 Phase classification: P1/2 --> P1 | N=39 --> 15 | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2021
|
